Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

The cost of Inlexzo can vary based on several factors, including your insurance coverage. Financial support may be available through the J&J withMe program, which offers assistance for eligible ...

The FDA has approved Inlexzo, the first intravesical drug-releasing device for bladder cancer, offering an alternative for patients whose disease no longer responds to BCG therapy. The device delivers ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited ...

Inlexzo is approved for BCG-unresponsive NMIBC with CIS, offering a new treatment option for patients with limited alternatives. The SunRISe-1 trial showed an 82% complete response rate, with 51% ...

Less than two months after receiving priority review status for an NDA, Johnson & Johnson won U.S. FDA approval of Inlexzo, its intravesical gemcitabine releasing system previously known as TAR-200, ...

Johnson & Johnson’s model fair value sits at US$252.87 per share, with analysts keeping price targets anchored to that unchanged estimate. Recent research links those steady targets to a mix of ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.